Lung CancerPOLCARNCT06480734
Pneumonitis in Older Lung Cancer Patients After Radiotherapy
A study testing symptom-based scoring system (symptom-questionnaire, paper version) in people with Lung Cancer, run by University Hospital Schleswig-Holstein at 5 sites in 2 countries.
Trial summary
The main goal of this trial is to establish the performance characteristics and to develop a decision-algorithm of a new symptom-based scoring system with respect to the identification of elderly lung cancer patients developing pneumonitis after radiotherapy. Read more about this study
- Who is it for?
- Ages 65 years and older
- Conditions the study is for
- Lung Cancer
- What is being tested?
- symptom-based scoring system (symptom-questionnaire, paper version)
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 62 participants
- Where
- 5 sitesin 2 countries
- Study dates
- 6 Nov 2024to 30 Jun 2026
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 65 years and older
- All sexes
- No healthy volunteers
- Older adult
Who may be able to join
- Histologically proven lung cancer
- Indication for radiotherapy or chemoradiation
- Mean radiation dose to ipsilateral lung >13 Gy
- Age ≥65 years
- Written informed consent
- Capacity of the patient to contract
Who cannot join
- Expected Non-Compliance
- Baseline score of >4 points
Trial locations and contacts
5 sites in 2 countries.
5 sites in 2 countries
Germany4 sites
Malteser Hospital St. Franziskus
Flensburg, Schleswig-Holstein, 24939
Medical Practice for Radiotherapy and Radiation Oncology
Hanover, Lower Saxony, 30161
Department of Radiation Oncology, University of Lübeck and University Medical Center Schleswig-Holstein
Lübeck, Schleswig-Holstein, 23562
Medical School Hamburg, Schwerin Campus
Schwerin, Mecklenburg-Vorpommern, 19055
Denmark1 site
Vejle Hospital, University Hospital of Southern Denmark
Vejle, Southern Denmark, 7100
About this study
Official title: Pneumonitis in Older Lung Cancer Patients After Radiotherapy: a Scoring System for Identification of Pneumonitis in Elderly Patients Irradiated for Lung Cancer
The main goal of this trial is to establish the performance characteristics and to develop a decision-algorithm of a new symptom-based scoring system with respect to the identification of elderly lung cancer patients developing pneumonitis after radiotherapy.
To assess the performance characteristics of the symptom-based scoring system for detection of radiation pneumonitis the receiver operating characteristic (ROC) curve is used to show the connection between sensitivity and specificity for every possible cut-off for the symptom-based scoring system and to select the optimal scoring point for detection of radiation pneumonitis. The area under the ROC curve (AUC) is calculated to prove the diagnostic ability of the scoring system.
Secondary aims include patient satisfaction with the symptom-based scoring system (symptom-questionnaire, paper version).
Read the detailed description
The present prospective study investigates, whether the results of the previous prospective trial can be generalized to elderly patients aged ≥65 years. Its major goal is the identification of the optimal cut-off score to correctly diagnose pneumonitis and discriminate it from other lung diseases in elderly patients irradiated for lung cancer. In addition, the diagnostic value of an increase of the scoring points from baseline scores is evaluated. This study is a prerequisite for the development of a mobile application, which can be used by the patients at home to rate their symptoms possibly related to pneumonitis. This information will contribute to the decision whether pneumonitis is possible or likely and whether any action (e.g. consulting a pulmonologist or visiting a hospital) is required.
The main goal of this trial is to establish the performance characteristics and to develop a decision-algorithm of a new symptom-based scoring system with respect to the identification of elderly patients developing pneumonitis after radiotherapy for lung cancer. To assess the performance characteristics of the symptom-based scoring system for detection of radiation pneumonitis in elderly lung cancer patients, the receiver operating characteristic (ROC) curve is used to show the connection between sensitivity and specificity for every possible cut-off for the scoring system and to select the optimal scoring point for detection of radiation pneumonitis. The area under the ROC curve (AUC) is calculated to assess the diagnostic ability of the scoring system. Secondary aims include patient satisfaction with the symptom-based scoring system (symptom-questionnaire, paper version), assessed at the end of radiotherapy.
In case of suspected pneumonitis, patients undergo lung function tests. The suspected diagnosis of pneumonitis is considered substantiated in case of a decrease in forced expiratory volume in 1 second (FEV1) and diffusing capacity of the lung for carbon monoxide (DLCO) to less than 75% from baseline values. In this situation, patients receive a chest x-ray (which may be supplemented by a computed tomography) in accordance with the current standard procedures at the corresponding participating center. Radiation pneumonitis is considered confirmed, if opacities confined to the irradiation fields are seen on chest x-ray and/or ground-glass opacities (focal or nodular), consolidation or both are seen on computed tomography [19, 20]. If the diagnosis symptomatic radiation pneumonitis (grade ≥2) has been confirmed, patients receive medical intervention. The vast majority of the patients receive prednisolone, which is considered the mainstay of the treatment for radiation pneumonitis. If pneumonitis is not confirmed and symptoms are caused by other (e.g. underlying) disease, the patients receive treatment for this situation.
The symptom-based sum score is correlated to pneumonitis (yes vs. no). At the end of radiotherapy, patients are asked to complete a questionnaire regarding their satisfaction with the score. In case of a dissatisfaction rate >20%, the score needs modifications before it can be used in future studies. In case of a dissatisfaction rate >40%, the symptom-based scoring system will be considered not useful.
Based on samplesize calculations, 59 subjects (18 with radiation pneumonitis and 41 without radiation pneumonitis) are required within the Full Analysis Set. Assuming that 5% of subjects will not qualify for Full Analysis Set, a total of 62 subjects should be enrolled.
The Full Analysis Set includes all subjects who started radiotherapy for lung cancer.
The primary aim of the study is to assess the performance characteristics of the symptom-based scoring system for detection of radiation pneumonitis. The evaluation will be performed in those subjects, who are available for assessment of the primary endpoint and have completed at least 10 questionnaires (paper version) regarding the symptom-based scoring system.
In order to allow for patient-based analyses, the multiple score values documented for each patient over time will be reduced to one clinically relevant, patient-specific value only. The following pragmatic and clinically persuasive approach is foreseen:
- For subjects without radiation pneumonitis during study, the maximum score value documented throughout study will be selected.
- For subjects experiencing radiation pneumonitis, the value documented at the time of diagnosis will be selected.
These patient-specific values represent the fundamental units for all further statistical analyses. First of all, sensitivity and specificity will be estimated for every possible cut-off value of the symptom-based scoring system.
The ROC curve is used to show in a graphical way the connection between sensitivity and specificity. The term ROC stands for Receiver Operating Characteristic and is defined as the plot of sensitivity versus 1-Specificity (false-positive rate) across varying cut-offs. A ROC curve corresponding to greater discriminant capacity of the symptom-based scoring system is located closer to the upper-left-hand corner. A ROC curve lying on the diagonal line reflects the performance of a diagnostic test that is no better than chance level.
The area under the curve (AUC) summarizes the entire location of the ROC curve. The AUC is an effective and combined measure of the sensitivity and specificity that describes the inherent validity of the usefulness of the test in general, where a greater area means a more useful test. If AUC=1 the symptom-based scoring system is perfect in the differentiation between subjects with and without radiation pneumonitis. This happens when the distribution of the score values for the subjects with and without events do not overlap. In contrast, AUC=0.5 means that the scoring system is performing no better than chance. Therefore, the AUC can be considered as a valuable quantitative measure to prove the diagnostic ability of the symptom-based scoring system. A rough guide for classifying the accuracy of a diagnostic test is the traditional academic point system (AUCs of 0.5 - 0.6 = fail; 0.6-0.7 poor; 0.7-0.8 = fair, 0.8-0.9 = good and 0.9-1 = excellent). Therefore, any symptom-based score leading to an AUC of at most 0.7 will be rated insufficiently useful and is not considered worth pursuing.
Based on this definition, the following hypothesis system will be subjected to statistical analysis:
H0: AUC=0.7 versus H1: AUC ≠0.7 Non-parametric methods for AUC estimation and testing using the normal approximation of the asymptotic properties of the AUC with standard errors derived by the method of DeLong, DeLong and Clarke-Pearson will be applied [25]. Technically, the SAS (SAS Institute Inc.) LOGISTIC procedure with the ROCCONTRAST statement can be used to estimate the AUC and its 95% confidence limit and to provide the p-value for the test mentioned above. A significance level of two-sided 5% is prespecified.
If statistical significance of the AUC is reached, the most-informative (optimal) scoring point to predict radiation pneumonitis will be established. Based on discussions with various experts, optimality is defined as a score cut-off value with at least 90% and the specificity at least 80%. In addition to this visual selection of a suitable cut-off value, the Youden index (sensitivity + specificity - 1) will be applied to propose an optimal cut-off value for further consideration.
Due to the limited sample size which could be realistically achieved in this multi-center trial within the given study duration, it is not considered feasible to develop and validate the optimal cut-off value identified within this single study at the same time by dividing the study population into training and validation cohorts. Therefore, the derived cut-off value should be considered as a preliminary suggestion which has to be validated in subsequent studies.
As a further sensitivity analysis, the relationship between tertiles of the symptom-based scores and the incidence of radiation pneumonitis will be statistically tested using the Jonckheere-Terpstra test which is a nonparametric test for ordered differences among groups of score values. It tests the global null hypothesis that the distribution of the response variable does not differ among tertiles. The test is designed to detect alternatives of ordered differences, meaning that the incidence of pneumonitis increases with the tertiles of score values.
- Conditions
- Lung Cancer
- Being tested
- symptom-based scoring system (symptom-questionnaire, paper version)
- Keywords
- Lung cancer, Radiotherapy, Pneumonitis, Scoring system
- Medical subject headings
- Lung Neoplasms, Pneumonia
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
symptom-based scoring system (symptom-questionnaire, paper version)Other
The patients are asked to complete a paper-based questionnaire (symptom-based scoring system, paper version) once a week during and up to 24 weeks following radiotherapy. The patients state and score symptoms potentially associated with pneumonitis, namely cough, shortness of breath and fever. Scoring points are assigned to severity of the symptoms, and sum scores are used to identify pneumonitis. During the radiotherapy course, patients complete the questionnaire prior to regular appointments with a physician. Following radiotherapy, they are contacted by phone (to minimize the number of hospital visits) once a week for completion of the questionnaire. In case of an increase of the total score when compared to baseline, patients receive a follow-up phone call after 3 days, are asked to come to the hospital as outpatients or are admitted to hospital.
| Study group | Role | What they receive |
|---|---|---|
| Elderly patients with lung cancer and risk of pneumonitis | Experimental | Elderly patients (65 years or older) irradiated for lung cancer who receive a mean radiation dose to the ipsilateral lung >13 Gy and, therefore, have an increased risk of developing radiation pneumonitis. Receives: Other: symptom-based scoring system (symptom-questionnaire, paper version) |
What is being measured
The primary outcome is the main question the study is designed to answer.
Number of participants with symptomatic radiation pneumonitis (grade ≥2)
Radiation pneumonitis will be assessed according to National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) v5.0.
Measured: start of radiotherapy until 24 weeks following radiotherapy
Secondary outcomes (1)
Rate of patient satisfaction
- Patient satisfaction with the symptom-based scoring system (symptom-questionnaire, paper version) will be assessed using a specific questionnaire.
Measured: at the end of radiotherapy
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted28 Jun 2024
- Study start6 Nov 2024
- Primary completion30 Jun 2026 (estimated)
- Study completion30 Jun 2026 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Lung CancerStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Diagnosis
- Allocation
- Not applicable
- Intervention model
- Single group
- Model description
- multi-center prospective study
- Masking
- None (open label)
- Enrolment
- 62 participants (estimated)
Sponsor and investigators
- Lead sponsor
- University Hospital Schleswig-Holstein
- Sponsor type
- University, hospital or other
- Collaborators
- University of Southern Denmark, Medical School Hamburg
- Responsible party
- Sponsor
- Investigators
- Dirk Rades, MD, FASTRO, Principal investigator, University of Lubeck
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT06480734
- Sponsor's protocol ID
- POLCAR
- Acronym
- POLCAR
- Status last verified
- Jan 2025
- First submitted
- 24 Jun 2024
- Last updated
- 16 Jan 2025
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 16 Jan 2025. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Pneumonitis in Older Lung Cancer Patients After Radiotherapy: a Scoring System for Identification of Pneumonitis in Elderly Patients Irradiated for Lung Cancer
- ClinicalTrials.gov ID
- NCT06480734
- Acronym / sponsor ID
- POLCAR / POLCAR
- Conditions
- Lung Cancer
- Keywords
- Lung cancer, Radiotherapy, Pneumonitis, Scoring system
- Study type
- Interventional
- Recruitment status
- Active, not recruiting
- Enrolment
- 62 participants (estimated)
- Lead sponsor
- University Hospital Schleswig-HolsteinUniversity, hospital or other
- Collaborators
- University of Southern Denmark, Medical School Hamburg
- Study start
- 6 Nov 2024 (actual)
- Primary completion
- 30 Jun 2026 (estimated)
- Study completion
- 30 Jun 2026 (estimated)
- First posted
- 28 Jun 2024 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The main goal of this trial is to establish the performance characteristics and to develop a decision-algorithm of a new symptom-based scoring system with respect to the identification of elderly lung cancer patients developing pneumonitis after radiotherapy.
To assess the performance characteristics of the symptom-based scoring system for detection of radiation pneumonitis the receiver operating characteristic (ROC) curve is used to show the connection between sensitivity and specificity for every possible cut-off for the symptom-based scoring system and to select the optimal scoring point for detection of radiation pneumonitis. The area under the ROC curve (AUC) is calculated to prove the diagnostic ability of the scoring system.
Secondary aims include patient satisfaction with the symptom-based scoring system (symptom-questionnaire, paper version).
Detailed description
The present prospective study investigates, whether the results of the previous prospective trial can be generalized to elderly patients aged ≥65 years. Its major goal is the identification of the optimal cut-off score to correctly diagnose pneumonitis and discriminate it from other lung diseases in elderly patients irradiated for lung cancer. In addition, the diagnostic value of an increase of the scoring points from baseline scores is evaluated. This study is a prerequisite for the development of a mobile application, which can be used by the patients at home to rate their symptoms possibly related to pneumonitis. This information will contribute to the decision whether pneumonitis is possible or likely and whether any action (e.g. consulting a pulmonologist or visiting a hospital) is required.
The main goal of this trial is to establish the performance characteristics and to develop a decision-algorithm of a new symptom-based scoring system with respect to the identification of elderly patients developing pneumonitis after radiotherapy for lung cancer. To assess the performance characteristics of the symptom-based scoring system for detection of radiation pneumonitis in elderly lung cancer patients, the receiver operating characteristic (ROC) curve is used to show the connection between sensitivity and specificity for every possible cut-off for the scoring system and to select the optimal scoring point for detection of radiation pneumonitis. The area under the ROC curve (AUC) is calculated to assess the diagnostic ability of the scoring system. Secondary aims include patient satisfaction with the symptom-based scoring system (symptom-questionnaire, paper version), assessed at the end of radiotherapy.
In case of suspected pneumonitis, patients undergo lung function tests. The suspected diagnosis of pneumonitis is considered substantiated in case of a decrease in forced expiratory volume in 1 second (FEV1) and diffusing capacity of the lung for carbon monoxide (DLCO) to less than 75% from baseline values. In this situation, patients receive a chest x-ray (which may be supplemented by a computed tomography) in accordance with the current standard procedures at the corresponding participating center. Radiation pneumonitis is considered confirmed, if opacities confined to the irradiation fields are seen on chest x-ray and/or ground-glass opacities (focal or nodular), consolidation or both are seen on computed tomography [19, 20]. If the diagnosis symptomatic radiation pneumonitis (grade ≥2) has been confirmed, patients receive medical intervention. The vast majority of the patients receive prednisolone, which is considered the mainstay of the treatment for radiation pneumonitis. If pneumonitis is not confirmed and symptoms are caused by other (e.g. underlying) disease, the patients receive treatment for this situation.
The symptom-based sum score is correlated to pneumonitis (yes vs. no). At the end of radiotherapy, patients are asked to complete a questionnaire regarding their satisfaction with the score. In case of a dissatisfaction rate >20%, the score needs modifications before it can be used in future studies. In case of a dissatisfaction rate >40%, the symptom-based scoring system will be considered not useful.
Based on samplesize calculations, 59 subjects (18 with radiation pneumonitis and 41 without radiation pneumonitis) are required within the Full Analysis Set. Assuming that 5% of subjects will not qualify for Full Analysis Set, a total of 62 subjects should be enrolled.
The Full Analysis Set includes all subjects who started radiotherapy for lung cancer.
The primary aim of the study is to assess the performance characteristics of the symptom-based scoring system for detection of radiation pneumonitis. The evaluation will be performed in those subjects, who are available for assessment of the primary endpoint and have completed at least 10 questionnaires (paper version) regarding the symptom-based scoring system.
In order to allow for patient-based analyses, the multiple score values documented for each patient over time will be reduced to one clinically relevant, patient-specific value only. The following pragmatic and clinically persuasive approach is foreseen:
- For subjects without radiation pneumonitis during study, the maximum score value documented throughout study will be selected.
- For subjects experiencing radiation pneumonitis, the value documented at the time of diagnosis will be selected.
These patient-specific values represent the fundamental units for all further statistical analyses. First of all, sensitivity and specificity will be estimated for every possible cut-off value of the symptom-based scoring system.
The ROC curve is used to show in a graphical way the connection between sensitivity and specificity. The term ROC stands for Receiver Operating Characteristic and is defined as the plot of sensitivity versus 1-Specificity (false-positive rate) across varying cut-offs. A ROC curve corresponding to greater discriminant capacity of the symptom-based scoring system is located closer to the upper-left-hand corner. A ROC curve lying on the diagonal line reflects the performance of a diagnostic test that is no better than chance level.
The area under the curve (AUC) summarizes the entire location of the ROC curve. The AUC is an effective and combined measure of the sensitivity and specificity that describes the inherent validity of the usefulness of the test in general, where a greater area means a more useful test. If AUC=1 the symptom-based scoring system is perfect in the differentiation between subjects with and without radiation pneumonitis. This happens when the distribution of the score values for the subjects with and without events do not overlap. In contrast, AUC=0.5 means that the scoring system is performing no better than chance. Therefore, the AUC can be considered as a valuable quantitative measure to prove the diagnostic ability of the symptom-based scoring system. A rough guide for classifying the accuracy of a diagnostic test is the traditional academic point system (AUCs of 0.5 - 0.6 = fail; 0.6-0.7 poor; 0.7-0.8 = fair, 0.8-0.9 = good and 0.9-1 = excellent). Therefore, any symptom-based score leading to an AUC of at most 0.7 will be rated insufficiently useful and is not considered worth pursuing.
Based on this definition, the following hypothesis system will be subjected to statistical analysis:
H0: AUC=0.7 versus H1: AUC ≠0.7 Non-parametric methods for AUC estimation and testing using the normal approximation of the asymptotic properties of the AUC with standard errors derived by the method of DeLong, DeLong and Clarke-Pearson will be applied [25]. Technically, the SAS (SAS Institute Inc.) LOGISTIC procedure with the ROCCONTRAST statement can be used to estimate the AUC and its 95% confidence limit and to provide the p-value for the test mentioned above. A significance level of two-sided 5% is prespecified.
If statistical significance of the AUC is reached, the most-informative (optimal) scoring point to predict radiation pneumonitis will be established. Based on discussions with various experts, optimality is defined as a score cut-off value with at least 90% and the specificity at least 80%. In addition to this visual selection of a suitable cut-off value, the Youden index (sensitivity + specificity - 1) will be applied to propose an optimal cut-off value for further consideration.
Due to the limited sample size which could be realistically achieved in this multi-center trial within the given study duration, it is not considered feasible to develop and validate the optimal cut-off value identified within this single study at the same time by dividing the study population into training and validation cohorts. Therefore, the derived cut-off value should be considered as a preliminary suggestion which has to be validated in subsequent studies.
As a further sensitivity analysis, the relationship between tertiles of the symptom-based scores and the incidence of radiation pneumonitis will be statistically tested using the Jonckheere-Terpstra test which is a nonparametric test for ordered differences among groups of score values. It tests the global null hypothesis that the distribution of the response variable does not differ among tertiles. The test is designed to detect alternatives of ordered differences, meaning that the incidence of pneumonitis increases with the tertiles of score values.
Study design
- Primary purpose
- Diagnosis
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Number of arms
- 1
- Model description
- multi-center prospective study
| Arm | Type | Receives |
|---|---|---|
| Elderly patients with lung cancer and risk of pneumonitis | Experimental | Other: symptom-based scoring system (symptom-questionnaire, paper version)Elderly patients (65 years or older) irradiated for lung cancer who receive a mean radiation dose to the ipsilateral lung >13 Gy and, therefore, have an increased risk of developing radiation pneumonitis. |
Who may qualify
- Ages
- 65 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Older adult
Key inclusion criteria (6 listed)
- Histologically proven lung cancer
- Indication for radiotherapy or chemoradiation
- Mean radiation dose to ipsilateral lung >13 Gy
- Age ≥65 years
- Written informed consent
Key exclusion criteria (2 listed)
- Expected Non-Compliance
- Baseline score of >4 points
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| symptom-based scoring system (symptom-questionnaire, paper version)The patients are asked to complete a paper-based questionnaire (symptom-based scoring system, paper version) once a week during and up to 24 weeks following radiotherapy. The patients state and score symptoms potentially associated with pneumonitis, namely cough, shortness of breath and fever. Scoring points are assigned to severity of the symptoms, and sum scores are used to identify pneumonitis. During the radiotherapy course, patients complete the questionnaire prior to regular appointments with a physician. Following radiotherapy, they are contacted by phone (to minimize the number of hospital visits) once a week for completion of the questionnaire. In case of an increase of the total score when compared to baseline, patients receive a follow-up phone call after 3 days, are asked to come to the hospital as outpatients or are admitted to hospital. | Other | Elderly patients with lung cancer and risk of pneumonitis |
Primary outcome
Number of participants with symptomatic radiation pneumonitis (grade ≥2)
Time frame: start of radiotherapy until 24 weeks following radiotherapy
Radiation pneumonitis will be assessed according to National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) v5.0.
1 secondary outcome
Rate of patient satisfaction
Time frame: at the end of radiotherapy
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 16 Jan 2025.
- Individual participant dataSharing planned: No
Related trials for Lung Cancer
RecruitingPhase 1/2
Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)
Solid Tumor, Non-Small Cell Lung Cancer
RecruitingObservational study
A Prospective ,Multicenter ,Non-interventional ,Real-world Study Observing Changes in Molecular Markers Osimertinib Targeted Therapy in EGFRm NSCLC
Non Small Cell Lung Cancer
Active, not recruiting
Streamlined Geriatric and Oncological Evaluation Based On IC Technology
Breast Cancer, Comorbidities and Coexisting Conditions
RecruitingPhase 3
A Study Evaluating Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Participants With Stage IV or Advanced Stage IIIB/C Nonsquamous Non-Small Cell Lung Cancers (CodeBreaK 202)
Non-Small Cell Lung Cancer (NSCLC)
Active, not recruitingPhase 2
Datopotamab Deruxtecan (Dato-DXd, DS-1062a) in Advanced and/or Unresectable Non-Small Cell Lung Cancer
Metastatic Lung Cancer, Advanced Non Small Cell Lung Cancer
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Dirk Rades, MD, FASTRO principal investigator
University of Lubeck
5 sites in 2 countries: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing symptom-based scoring system (symptom-questionnaire, paper version) in people with Lung Cancer, run by University Hospital Schleswig-Holstein at 5 sites in 2 countries.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 6 inclusion and 2 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: under way, not looking for participants, as of the sponsor's last update on 16 Jan 2025. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 5 sites in Germany, Denmark. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Number of participants with symptomatic radiation pneumonitis (grade ≥2) (time frame: start of radiotherapy until 24 weeks following radiotherapy). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 16 Jan 2025.